Warning: The NCBI web site requires JavaScript to function. more...
Generate a file for use with external citation management software.
Preventative tools of the future: predicting the individual risk of cytomegalovirus infection after transplant.
Kotton CN.
Transplantation. 2012 Mar 15;93(5):467-8. No abstract available.
Related citations
Clinical utility of cytomegalovirus cell-mediated immunity in transplant recipients with cytomegalovirus viremia.
Lisboa LF, Kumar D, Wilson LE, Humar A.
Transplantation. 2012 Jan 27;93(2):195-200.
Valganciclovir prophylaxis versus preemptive therapy in cytomegalovirus-positive renal allograft recipients: 1-year results of a randomized clinical trial.
Witzke O, Hauser IA, Bartels M, Wolf G, Wolters H, Nitschke M; VIPP Study Group.
Transplantation. 2012 Jan 15;93(1):61-8.
Summary of the British Transplantation Society Guidelines for the Prevention and Management of CMV Disease After Solid Organ Transplantation.
Andrews PA, Emery VC, Newstead C.
Transplantation. 2011 Dec 15;92(11):1181-7. Review.
Everolimus prevents endomyocardial remodeling after heart transplantation.
Hiemann NE, Wellnhofer E, Lehmkuhl HB, Knosalla C, Hetzer R, Meyer R.
Transplantation. 2011 Nov 27;92(10):1165-72.
A universal preemptive therapy for cytomegalovirus infections in children after live-donor liver transplantation.
Saitoh A, Sakamoto S, Fukuda A, Shigeta T, Kakiuchi T, Kamiyama S, Katsuta T, Shoji K, Ogimi C, Kasahara M.
Transplantation. 2011 Oct 27;92(8):930-5.
Epidemiology of cytomegalovirus infection after pancreas transplantation.
Parsaik AK, Bhalla T, Dong M, Rostambeigi N, Dierkhising RA, Dean P, Abraham R, Prieto M, Kremers WK, Razonable RR, Kudva YC.
Transplantation. 2011 Nov 15;92(9):1044-50.
Ganciclovir transiently attenuates murine cytomegalovirus-associated renal allograft inflammation.
Shimamura M, Saunders U, Rha B, Guo L, Cassady KA, George JF, Britt WJ.
Transplantation. 2011 Oct 15;92(7):759-66.
Clinical utility of molecular surveillance for cytomegalovirus after antiviral prophylaxis in high-risk solid organ transplant recipients.
Lisboa LF, Preiksaitis JK, Humar A, Kumar D.
Transplantation. 2011 Nov 15;92(9):1063-8.
Immunological monitoring for guidance of preemptive antiviral therapy for active cytomegalovirus infection in allogeneic stem-cell transplant recipients: a pilot experience.
Solano C, Benet I, Remigia MJ, de la Cámara R, Muñoz-Cobo B, Costa E, Clari MÁ, Bravo D, Amat P, Navarro D.
Transplantation. 2011 Aug 27;92(4):e17-20. No abstract available.
The effect of donor-recipient cytomegalovirus serology on adult liver transplantation: a single center experience.
Tryphonopoulos P, Weppler D, Morris MI, Russo C, Nishida S, Levi DM, Moon J, Tekin A, Selvaggi G, Island E, Arosemena L, Ruiz P, Tzakis AG.
Transplantation. 2011 Nov 15;92(9):1051-7.
Incidence and outcomes of ganciclovir-resistant cytomegalovirus infections in 1244 kidney transplant recipients.
Myhre HA, Haug Dorenberg D, Kristiansen KI, Rollag H, Leivestad T, Asberg A, Hartmann A.
Transplantation. 2011 Jul 27;92(2):217-23.
Cytomegalovirus neutralization by hyperimmune and standard intravenous immunoglobulin preparations.
Planitzer CB, Saemann MD, Gajek H, Farcet MR, Kreil TR.
Transplantation. 2011 Aug 15;92(3):267-70.
Unraveling the biologic basis of late-onset cytomegalovirus disease in high-risk organ transplant recipients.
Singh N.
Transplantation. 2011 Apr 27;91(8):825-6. No abstract available.
Therapeutic effect of the acquisition of cytomegalovirus-specific immune response during preemptive treatment.
Benmarzouk-Hidalgo OJ, Cisneros JM, Cordero E, Martín-Peña A, Sanchez B, Martin-Gandul C, Gentil MA, Gomez-Bravo MA, Lage E, Perez-Romero P.
Transplantation. 2011 Apr 27;91(8):927-33.
The 5-year outcome of ABO-incompatible kidney transplantation with rituximab induction.
Fuchinoue S, Ishii Y, Sawada T, Murakami T, Iwadoh K, Sannomiya A, Koyama I, Kubota K, Tojimbara T, Nakajima I, Teraoka S.
Transplantation. 2011 Apr 27;91(8):853-7.
Why valganciclovir should not be indicated for liver recipients and high-dose acyclovir should not be removed from international cytomegalovirus guidelines.
Kalil AC, Florescu DF.
Transplantation. 2011 Jan 15;91(1):e8-9; author reply e10. No abstract available.
Extended valganciclovir prophylaxis in D+/R- kidney transplant recipients is associated with long-term reduction in cytomegalovirus disease: two-year results of the IMPACT study.
Humar A, Limaye AP, Blumberg EA, Hauser IA, Vincenti F, Jardine AG, Abramowicz D, Ives JA, Farhan M, Peeters P.
Transplantation. 2010 Dec 27;90(12):1427-31.
Universal prophylaxis is cost effective in cytomegalovirus serology-positive kidney transplant patients.
Luan FL, Kommareddi M, Ojo AO.
Transplantation. 2011 Jan 27;91(2):237-44.
Impact of a preemptive strategy after 3 months of valganciclovir cytomegalovirus prophylaxis in kidney transplant recipients.
Boillat Blanco N, Pascual M, Venetz JP, Nseir G, Meylan PR, Manuel O.
Transplantation. 2011 Jan 27;91(2):251-5.
Filters: Manage Filters
Your browsing activity is empty.
Activity recording is turned off.
Turn recording back on